US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

NEW YORK, DE, UNITED STATES, June 6, 2025 /EINPresswire.com/ -- The global nasal sprays market is projected to grow from USD ...

The VeriTac-2 trial assessed vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2* ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...